FDA Inspection 1203658 — LifeSan Clinical Research
The FDA completed an inspection of LifeSan Clinical Research on February 24, 2023 in Mumbai. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 24, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Mumbai (India)
Additional Details
Bioanalytical BA/BE